Vibiosphen is a healthcare biotechnology startup specializing in infectious diseases, established in 2014. Embracing the One Health concept, which emphasizes the interconnectedness of human, animal, and environmental health, the company is dedicated to developing new anti-infective therapies and rejuvenating the antibiotic pipeline. With over 7 years of expertise, Vibiosphen offers comprehensive support for preclinical studies aimed at combatting infectious diseases.
As an innovative player in the industry, Vibiosphen's range of services includes pre-clinical assessments of new therapies using a diverse array of mouse experimental models and in vitro predictive models. Their customized approach caters to the unique needs of their clients, ensuring a tailored and effective strategy in the fight against infectious diseases.
Specializing in Biotechnology, Health Care, and Pharmaceutical industries, Vibiosphen's commitment to addressing global health challenges position them as a noteworthy prospect for potential investors seeking opportunities in the biotechnology sector.
-logo.jpg "Mid-Atlantic BioTherapeutics (MABT)"){kind=logo}
